gdc
PSSGuide_2021
Melanoma

Drugs for Melanoma

Here are the drugs and financial support services available to patients receiving treatment for Melanoma.

Braftovi (encorafenib) + Mektovi (binimetinib)

Drug company: Pfizer
877-744-5675

Braftovi plus Mektovi are 2 kinase inhibitors that are used together for the treatment of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Braftovi + Mektovi:

Pfizer Oncology Together Co-Pay Savings Program

Eligible patients with commercial insurance may pay as little as $0 per month for Braftovi + Mektovi through this program. This program has no income requirements, and no forms to fill or fax to enroll.

Pfizer Patient Assistance Program

Patients with Medicare Part D, Medicaid, or any other government insurance plan may be able to receive Braftovi + Mektovi for free through Pfizer Oncology Together and Pfizer Patient Assistance. Uninsured patients may be able to receive Braftovi + Mektovi for free through the Pfizer Patient Assistance Program, or at a savings through the Pfizer Savings Program.

Cotellic (cobimetinib) Tablets

Drug company: Genentech
866-422-2377

Cotellic is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with Zelboraf.

Genentech Oncology offers 2 financial assistance programs for patients using Cotellic:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Cotellic, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Cotellic free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Cotellic is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Imlygic (talimogene laherparepvec)

Drug company: Amgen
888-427-7478

Imlygic is a genetically modified oncolytic viral therapy used for the treatment of unresectable cutaneous, subcutaneous, or nodal lesions in patients with melanoma.

Amgen offers 2 financial assistance programs for patients using Imlygic:

Amgen FIRST STEP Program

For privately insured patients whose insurance covers Imlygic, this program ensures a copay of $0 for the first dose and $5 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Eligible patients who are uninsured, underinsured, or have Medicare coverage may be able to receive Imlygic for free through this program.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1-blocking antibody used for the treatment of patients with unresectable or metastatic melanoma. Keytruda is also used for the adjuvant treatment of patients with melanoma that involves the lymph node(s), after complete resection of the tumor.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have an annual household income of $63,800 or less for individuals, $86,200 or less for couples, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines, may request that an exception be made, provided that their household income is not above a set limit.

Mekinist (trametinib)

Drug company: Novartis
800-245-5356

Mekinist is a kinase inhibitor used, as a single agent or in combination with Tafinlar, for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E or V600K mutation, as detected by an FDA-approved test. Mekinist, in combination with Tafinlar, is also used for adjuvant treatment of patients with melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), after complete resection (tumor removal).

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Mekinist:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and co-insurance for Mekinist. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Mekinist for free until prescription drug coverage becomes available to them.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with unresectable or metastatic melanoma, as a single agent or in combination with Yervoy. Opdivo is also used in patients with melanoma and lymph node involvement or metastatic melanoma after complete resection in the adjuvant setting.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per drug (or $50,000 annually for 2 BMS drugs administered in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Tafinlar (dabrafenib)

Drug company: Novartis
800-245-5356

Tafinlar is a kinase inhibitor used, as a single agent or in combination with Mekinist, for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E mutation, as detected by an FDA-approved test. Tafinlar, in combination with Mekinist, is also used for adjuvant treatment of patients with melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), after complete resection (tumor removal).

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tafinlar:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and co-insurance for Tafinlar. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Tafinlar for free until prescription drug coverage becomes available to them.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used, in combination with Cotellic and Zelboraf, for the treatment of patients with unresectable or metastatic melanoma and BRAF V600 mutation.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Tecentriq:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Yervoy (ipilimumab)

Drug company: Bristol Myers Squibb
800-861-0048

Yervoy is a CTLA-4-blocking antibody used, alone or in combination with Opdivo, for the treatment of unresectable or metastatic melanoma in patients aged 12 years or older. Yervoy is also used as adjuvant treatment for patients with cutaneous melanoma and pathologic involvement of regional lymph nodes who have undergone complete resection, including total lymphadenectomy.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per drug (or $50,000 annually for 2 BMS drugs administered in combination).

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Zelboraf (vemurafenib)

Drug company: Genentech
866-422-2377

Zelboraf is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E mutation.

Genentech Oncology offers 2 financial assistance programs for patients using Zelboraf:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Zelboraf, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Zelboraf free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Zelboraf is also provided free for patients who are unable to afford their out-ofpocket costs and cannot find other financial assistance.

Table. Drugs Prescribed for Melanoma

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of unresectable or metastatic melanoma

    Adjuvant treatment of melanoma that involves the lymph node(s), after complete resection
  • Patient support services
  • Merck Co-pay Assistance Program
    800-727-5400

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Mekinist (trametinib)
  • Drug company
  • Novartis
  • Indication
  • Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as a single agent or in combination with Tafinlar

    Adjuvant treatment, in combination with Tafinlar, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection
  • Patient support services
  • Novartis Oncology Universal Co-pay Program
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254


    Drug name (generic name)
  • Tafinlar (dabrafenib)
  • Drug company
  • Novartis
  • Indication
  • Unresectable or metastatic melanoma with BRAF V600E mutation, as a single agent or in combination with Mekinist

    Adjuvant treatment, in combination with Mekinist, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection
  • Patient support services
  • Novartis Oncology Universal Co-pay program
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254




Share this:

Last modified: April 8, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest